Close Menu

NEW YORK ─ ContextVision said Monday that it has been granted CE marking for its Inify Prostate Screening digital pathology product, making it available for routine clinical use in the European Union.

Stockholm-based ContextVision said its Inify Prostate Screening artificial intelligence-based software predicts, outlines, and quantifies suspected cancerous areas in a series of prostate biopsies. It presorts slides in a worst-first order, allowing pathologists to work immediately on the most relevant areas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.